

Pembrolizumab KEYNOTE-189

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Long-term plateau in the survival



Pembrolizumab KEYNOTE-189

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: In combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive tumour mutations  
Experimental Arm: Pembrolizumab + Pemetrexed + platinum chemotherapy  
Control Arm: Placebo + pemetrexed + platinum chemotherapy



